Univariate and multivariate analysis of risk factors for alloimmunization and platelet refractoriness
. | Univariate . | . | Multivariate . | . | ||
|---|---|---|---|---|---|---|
. | RR (95% CI) . | P . | RR (95% CI) . | P . | ||
| Alloimmunization* | ||||||
| Nonleukoreduced blood | 2.3 (1.4-3.7) | .001 | 1.9 (1.1-3.1) | .014 | ||
| Female sex | 1.9 (1.2-3.0) | .005 | — | — | ||
| Parous/transfused | 2.6 (1.6-4.2) | < .001 | 2.5 (1.5-4.1) | < .001 | ||
| No. of platelet transfusions† | 5.3 (2.6-10.5) | < .001 | 4.7 (2.4-9.6) | < .001 | ||
| Platelet refractoriness‡ | ||||||
| Nonleukoreduced blood | 1.7 (1.3-2.3) | < .001 | 1.4 (1.0-1.9) | .034 | ||
| Parous/transfused | 1.5 (1.1-2.0) | .001 | 1.4 (1.1-2.0) | .002 | ||
| No. of platelet transfusions | 3.9 (2.7-5.7) | < .001 | 3.7 (2.6-5.4) | < .001 | ||
| Alloimmune platelet refractoriness§ | ||||||
| Nonleukoreduced blood | 2.8 (1.4-5.3) | .002 | 2.2 (1.2-4.3) | .016 | ||
| Female sex | 2.4 (1.4-4.1) | < .001 | — | — | ||
| Parous/transfused | 2.4 (1.3-4.4) | .004 | 2.3 (1.3-4.2) | .007 | ||
| No. of platelet transfusions | 6.8 (2.7-17.1) | < .001 | 6.0 (2.4-15.3) | .001 | ||
. | Univariate . | . | Multivariate . | . | ||
|---|---|---|---|---|---|---|
. | RR (95% CI) . | P . | RR (95% CI) . | P . | ||
| Alloimmunization* | ||||||
| Nonleukoreduced blood | 2.3 (1.4-3.7) | .001 | 1.9 (1.1-3.1) | .014 | ||
| Female sex | 1.9 (1.2-3.0) | .005 | — | — | ||
| Parous/transfused | 2.6 (1.6-4.2) | < .001 | 2.5 (1.5-4.1) | < .001 | ||
| No. of platelet transfusions† | 5.3 (2.6-10.5) | < .001 | 4.7 (2.4-9.6) | < .001 | ||
| Platelet refractoriness‡ | ||||||
| Nonleukoreduced blood | 1.7 (1.3-2.3) | < .001 | 1.4 (1.0-1.9) | .034 | ||
| Parous/transfused | 1.5 (1.1-2.0) | .001 | 1.4 (1.1-2.0) | .002 | ||
| No. of platelet transfusions | 3.9 (2.7-5.7) | < .001 | 3.7 (2.6-5.4) | < .001 | ||
| Alloimmune platelet refractoriness§ | ||||||
| Nonleukoreduced blood | 2.8 (1.4-5.3) | .002 | 2.2 (1.2-4.3) | .016 | ||
| Female sex | 2.4 (1.4-4.1) | < .001 | — | — | ||
| Parous/transfused | 2.4 (1.3-4.4) | .004 | 2.3 (1.3-4.2) | .007 | ||
| No. of platelet transfusions | 6.8 (2.7-17.1) | < .001 | 6.0 (2.4-15.3) | .001 | ||
—indicates not significant.
Positive lymphocytotoxic antibody screen on 2 or more consecutive occasions.
Receipt of 13 or more platelet transfusions (the median number of platelet transfusions for entire patient group).
There were 2 consecutive corrected count increments of less than 5.
Refractoriness within 2 weeks of 2 or more consecutive positive LCTAb screens.